203512-83-8

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 150691-04-6 2-(tert-butylamino)sulfonylphenylboronic acid 
• 497-19-8 sodium carbonate 

Downstream Products

• 1026000-24-7 3-(3-cyano-phenyl)-5-methyl-4,5-dihydro-isoxazole-5-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 
• 231300-26-8 5-isoxazolecarboxamide, 3-(3-cyanophenyl)-N-<5-<2'-(tert-butylaminosulfonyl)phenyl>-2-pyridinyl>-4,5-dihydro-5-(3-methoxymethyl)- 
• 231300-33-7 5-isoxazolecarboxamide, 3-(3-cyanophenyl)-N-<5-<2'-(tertbutylaminosulfonyl)phenyl>-2-pyridinyl>-4,5-dihydro-5-(ethylthiomethyl)- 
• 1025926-50-4 3-(3-cyano-phenyl)-5-ethoxymethyl-4,5-dihydro-isoxazole-5-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 
• 209959-17-1 2-(3-cyano-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 
• 1026272-62-7 2-(4-methoxy-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 
• 1026554-09-5 2-(4-methoxy-phenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 
• 288309-14-8 (2E) N-{5-[(2-tert-butylaminosulfonyl)phenyl]-pyridin-2yl}-3-(isoquinolin-7-yl)-2-fluoro-3-methylacrylamide 
• 218138-64-8 N-[5-(2-t-butylaminosulfonyl)phenylpyrid-2-yl]-2-(3'-cyanophenyl)nicotinamide 
• 316364-43-9 2-(5-cyano-1H-indol-3-yl)-N-[5-(2-sulfamoyl-phenyl)-pyridin-2-yl]-acetamide 
• 218301-61-2 3-(3-cyano-4-fluorophenyl)-5-[[5-[(2'-t-butylaminosulfonyl)phenyl]pyrid-2-yl]aminocarbonyl]-5-(methylsulfonylaminomethyl)isoxazoline 
• 609812-19-3 3-(4-chloro-3-nitro-phenyl)-5-tetrazol-1-ylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2-yl]-amide 

Relevant academic research and scientific papers

Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof

The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders.

OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS

The present application describes oxygen and sulfur containing heteroaromatics and derivatives thereof of formula (I), or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is O or S and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

Phenyl-isoxazoles as factor XA Inhibitors

The present application describes oxygen and sulfur containing heteroaromatics and derivatives thereof of formula or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is O or S and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

6-membered aromatics as factor Xa inhibitors

The present application describes 6-membered aromatics of formula I: or pharmaceutically acceptable salt forms thereof, wherein D may be CH2NH2 or C(=NH)NH2, which are useful as inhibitors of factor Xa.

Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors

Thrombotic diseases are a major cause of death and morbidity. Factor Xa (fXa) plays a vital role in the regulation of normal homeostasis and abnormal intravascular thrombus development in the blood coagulation cascade. A novel series of fXa inhibitors inc

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1

Thrombosis is a major cause of mortality in the industrialized world. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly re